Abstract
A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have